Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 4
2017 1
2019 2
2020 1
2021 2
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
Pharmacogenetics of siponimod: A systematic review.
Díaz-Villamarín X, Piñar-Morales R, Barrero-Hernández FJ, Antúnez-Rodríguez A, Cabeza-Barrera J, Morón-Romero R. Díaz-Villamarín X, et al. Biomed Pharmacother. 2022 Sep;153:113536. doi: 10.1016/j.biopha.2022.113536. Epub 2022 Aug 12. Biomed Pharmacother. 2022. PMID: 36076616 Free article. Review.
Pharmacogenetic polymorphisms affecting bisoprolol response.
Castaño-Amores C, Díaz-Villamarín X, Pérez-Gutiérrez AM, Antúnez-Rodríguez A, Pozo-Agundo A, Moreno-Escobar E, Sánchez-Ramos JG, Martínez-González LJ, Dávila-Fajardo CL. Castaño-Amores C, et al. Among authors: diaz villamarin x. Biomed Pharmacother. 2021 Oct;142:112069. doi: 10.1016/j.biopha.2021.112069. Epub 2021 Aug 27. Biomed Pharmacother. 2021. PMID: 34470728 Free article.
Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine.
Dávila-Fajardo CL, Díaz-Villamarín X, Antúnez-Rodríguez A, Fernández-Gómez AE, García-Navas P, Martínez-González LJ, Dávila-Fajardo JA, Barrera JC. Dávila-Fajardo CL, et al. Among authors: diaz villamarin x. Genes (Basel). 2019 Apr 1;10(4):261. doi: 10.3390/genes10040261. Genes (Basel). 2019. PMID: 30939847 Free PMC article. Review.
Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study.
Koufaki MI, Fragoulakis V, Díaz-Villamarín X, Karamperis K, Vozikis A, Swen JJ, Dávila-Fajardo CL, Vasileiou KZ, Patrinos GP, Mitropoulou C. Koufaki MI, et al. Among authors: diaz villamarin x. Hum Genomics. 2023 Jun 7;17(1):51. doi: 10.1186/s40246-023-00495-3. Hum Genomics. 2023. PMID: 37287029 Free PMC article.
Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients.
Blánquez-Martínez D, Díaz-Villamarín X, Antúnez-Rodríguez A, Pozo-Agundo A, Muñoz-Ávila JI, Martínez-González LJ, Dávila-Fajardo CL. Blánquez-Martínez D, et al. Among authors: diaz villamarin x. Pharmaceutics. 2021 Nov 20;13(11):1973. doi: 10.3390/pharmaceutics13111973. Pharmaceutics. 2021. PMID: 34834388 Free PMC article.
Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients.
Blánquez-Martínez D, Díaz-Villamarín X, García-Rodríguez S, Antúnez-Rodríguez A, Pozo-Agundo A, Martínez-González LJ, Muñoz-Ávila JI, Dávila-Fajardo CL. Blánquez-Martínez D, et al. Among authors: diaz villamarin x. Pharmaceutics. 2022 Jul 26;14(8):1555. doi: 10.3390/pharmaceutics14081555. Pharmaceutics. 2022. PMID: 35893809 Free PMC article.
Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention.
Fragoulakis V, Bartsakoulia M, Díaz-Villamarín X, Chalikiopoulou K, Kehagia K, Ramos JGS, Martínez-González LJ, Gkotsi M, Katrali E, Skoufas E, Vozikis A, John A, Ali BR, Wordsworth S, Dávila-Fajardo CL, Katsila T, Patrinos GP, Mitropoulou C. Fragoulakis V, et al. Among authors: diaz villamarin x. Pharmacogenomics J. 2019 Oct;19(5):438-445. doi: 10.1038/s41397-019-0069-1. Epub 2019 Jan 16. Pharmacogenomics J. 2019. PMID: 30647444
Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis.
Díaz-Villamarín X, Blánquez-Martínez D, Pozo-Agundo A, Pérez-Gutiérrez AM, Muñoz-Ávila JI, Antúnez-Rodríguez A, Fernández-Gómez AE, García-Navas P, Martínez-González LJ, Dávila-Fajardo CL. Díaz-Villamarín X, et al. Genes (Basel). 2020 Nov 12;11(11):1335. doi: 10.3390/genes11111335. Genes (Basel). 2020. PMID: 33198211 Free PMC article.
14 results